Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ce-224535. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 known ✓ | Q99572 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ce-224535 SCHEMBL3473554 | 1.00 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL13433834 | 1.00 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL3473601 | 1.00 | P2RX7 (1.00) | P2RX7 | |
| Ce-224535 SCHEMBL3473047 | 1.00 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL13433833 | 1.00 | P2RX7 (1.00) | P2RX7 | |
| Ce-224535 SCHEMBL31722367 | 1.00 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL3475207 | 1.00 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL3472374 | 0.99 | P2RX7 (0.98) | P2RX7 | |
| SCHEMBL13433836 | 0.99 | P2RX7 (0.98) | P2RX7 | |
| SCHEMBL13433835 | 0.99 | P2RX7 (0.98) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| WO-2025229484-A1 | PURINERGIC P2 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF CONGENITAL SIDEROBLASTIC ANEMIAS | UNIVERSITÀ DEGLI STUDI DI BARI ALDO MORO (IT) | 2025-11-06 | — | — | WO | claimed |
| US-20250129093-A1 | COMPOSITIONS AND METHODS RELATING TO ATP/P2X7R SIGNALING INHIBITION | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-04-24 | — | — | US | claimed |
| EP-4479366-A2 | COMPOSITIONS AND METHODS RELATING TO ATP/P2X7R SIGNALING INHIBITION | The Children's Medical Center Corporation (US) | 2024-12-25 | — | — | EP | claimed |
| WO-2024189127-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | PROLEVI BIO AB (SE) | 2024-09-19 | — | — | WO | claimed |
| WO-2023158601-A2 | COMPOSITIONS AND METHODS RELATING TO ATP/P2X7R SIGNALING INHIBITION | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-08-24 | — | — | WO | claimed |
| EP-4157288-A2 | MODULATORS OF PURINERGIC RECEPTORS AND RELATED IMMUNE CHECKPOINT FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROM | Institut Gustave-Roussy (FR) | 2023-04-05 | — | — | EP | claimed |
| US-7671053-B2 | Benzamide inhibitors of the P2X7 receptor | PFIZER, INC. (US) | 2010-03-02 | — | — | US | claimed |
| EP-1776352-A1 | METHOD FOR PREPARING 5-[4-(2-HYDROXY-PROPYL)-3,5-DIOXO-4,5-DIHYDRO-3H[1,2,4]TRIAZIN-2-YL]-BENZAMIDE DERIVATIVES BY DEPROTECTING THE HYDROXYL-PROTECTED PRECURSERS | Pfizer Products Inc. (US) | 2007-04-25 | — | — | EP | claimed |
| EP-1768965-A1 | METHOD FOR PREPARING 5-¬4-(2-HYDROXY-ETHYL)-3,5-DIOXO-4,5-DIHYDRO-3H-¬1,2,4|-TRIAZIN-2-YL|BENZAMIDE DERIVATIVES WITH P2X7 INHIBITING ACTIVITY BY REACTION OF THE DERIVATIVE UNSUBSTITUTED IN 4-POSITION OF THE TRIAZINE WITH AN OXIRAN IN THE PRESENCE OF A LEWIS ACID | Pfizer Products Incorporated (US) | 2007-04-04 | — | — | EP | claimed |
| WO-2006003500-A1 | METHOD FOR PREPARING 5-`4-(2-HYDROXY-PROPYL)-3,5-DIOXO-4,5-DIHYDRO-3H`1,2,4!TRIAZIN-2-YL!-BENZAMIDE DERIVATIVES BY DEPROTECTING THE HYDROXYL-PROTECTED PRECURSERS | PFIZER PRODUCTS INC. (US) | 2006-01-12 | — | — | WO | claimed |
| WO-2006003513-A1 | METHOD FOR PREPARING 5-`4-(2-HYDROXY-ETHYL)-3,5-DIOXO-4,5-DIHYDRO-3H-`1,2,4!-TRIAZIN-2-YL!BENZAMIDE DERIVATIVES WITH P2X7 INHIBITING ACTIVITY BY REACTION OF THE DERIVATIVE UNSUBSTITUTED IN 4-POSITION OF THE TRIAZINE WITH AN OXIRAN IN THE PRESENCE OF A LEWIS ACID | PFIZER PRODUCTS INC. (US) | 2006-01-12 | — | — | WO | claimed |
| US-20050288256-A1 | Methods for preparing P2X7 inhibitors | PFIZER INC. | 2005-12-29 | — | — | US | claimed |
| US-20050288288-A1 | Methods for preparing P2X7 inhibitors | PFIZER INC. | 2005-12-29 | — | — | US | claimed |
| US-6974812-B2 | Benzamide inhibitors of the P2X7 Ereceptor | PFIZER INC. (US) | 2005-12-13 | — | — | US | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12599664-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| US-20050288256-A1 | Methods for preparing P2X7 inhibitors | PFIZER INC. | 2005-12-29 | — | — | US | disclosed |
| US-20050288288-A1 | Methods for preparing P2X7 inhibitors | PFIZER INC. | 2005-12-29 | — | — | US | disclosed |
| US-20050288288-A1 | Methods for preparing P2X7 inhibitors | PFIZER INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599664-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | IL17A, IL15, IL5 | P2RX7 313/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | P2RX7 2434/4885 |
| US-20250129093-A1 | COMPOSITIONS AND METHODS RELATING TO ATP/P2X7R SIGNALING INHIBITION | P2RY1, P2RX3, P2RX1 | P2RX7 4/4885 |
| US-20050288256-A1 | Methods for preparing P2X7 inhibitors | P2RX7, P2RX1, P2RX3 | P2RX7 1/4885 |
| US-20050288288-A1 | Methods for preparing P2X7 inhibitors | P2RX7, P2RX1, P2RX2 | P2RX7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.